Cargando…
Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?
INTRODUCTION: Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option...
Autores principales: | Descalço, N., Medeiros, A.B., Santos, C. Fernandes, Borges, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476072/ http://dx.doi.org/10.1192/j.eurpsy.2021.1114 |
Ejemplares similares
-
The cognitive effects of esketamine: what do we know so far?
por: Barbosa, M., et al.
Publicado: (2022) -
Obsessive-Compulsive Disorder and suicide: what do we know up until now?
por: Salvadori, G., et al.
Publicado: (2022) -
Amyloidogenesis: What Do We Know So Far?
por: Alraawi, Zeina, et al.
Publicado: (2022) -
Effects of the COVID-19 pandemic on mental health - what do we know so far?
por: Marguilho, M., et al.
Publicado: (2021) -
Anabaenopeptins: What We Know So Far
por: Monteiro, Patrick Romano, et al.
Publicado: (2021)